APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Viral Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025199 pages

Choose your research edition.

Industry ResearchViral Vaccines Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vaccines Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Viral Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vaccines Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Viral Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Viral Vaccines include GSK, Sanofi, Novartis, Merck, Pfizer, Bayer, Zoetis, Johnson and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Viral Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Viral Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Viral Vaccines Segment by Company

GSK

Sanofi

Novartis

Merck

Pfizer

Bayer

Zoetis

Johnson

CSL

AstraZeneca

Viral Vaccines Segment by Type

Attenuated Vaccine

Inactivated Vaccine

Viral Vaccines Segment by Application

Research Institute

Hospital

Pharmaceutical Factory

Others

Viral Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Viral Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Viral Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Viral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Viral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Viral Vaccines Industry Trends Table 2. Viral Vaccines Industry Drivers Table 3. Viral Vaccines Industry Opportunities and Challenges Table 4. Viral Vaccines Industry Restraints Table 5. Global Viral Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Viral Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Viral Vaccines Sales by Manufacturers (W Tons) & (2021-2026) Table 8. Global Viral Vaccines Sales Market Share by Manufacturers Table 9. Global Viral Vaccines Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Viral Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Viral Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Viral Vaccines Manufacturers, Product Type & Application Table 13. Global Viral Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Viral Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Attenuated Vaccine Table 17. Major Manufacturers of Inactivated Vaccine Table 18. Global Viral Vaccines Sales by Type 2021 VS 2025 VS 2032 (W Tons) Table 19. Global Viral Vaccines Sales by Type (2021-2026) & (W Tons) Table 20. Global Viral Vaccines Sales by Type (2027-2032) & (W Tons) Table 21. Global Viral Vaccines Sales Market Share by Type (2021-2026) Table 22. Global Viral Vaccines Sales Market Share by Type (2027-2032) Table 23. Global Viral Vaccines Revenue by Type 2021 VS 2025 VS 2032 (W Tons) Table 24. Global Viral Vaccines Revenue by Type (2021-2026) & (W Tons) Table 25. Global Viral Vaccines Revenue by Type (2027-2032) & (W Tons) Table 26. Global Viral Vaccines Revenue Market Share by Type (2021-2026) Table 27. Global Viral Vaccines Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Research Institute Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Pharmaceutical Factory Table 31. Major Manufacturers of Others Table 32. Global Viral Vaccines Sales by Application 2021 VS 2025 VS 2032 (W Tons) Table 33. Global Viral Vaccines Sales by Application (2021-2026) & (W Tons) Table 34. Global Viral Vaccines Sales by Application (2027-2032) & (W Tons) Table 35. Global Viral Vaccines Sales Market Share by Application (2021-2026) Table 36. Global Viral Vaccines Sales Market Share by Application (2027-2032) Table 37. Global Viral Vaccines Revenue by Application 2021 VS 2025 VS 2032 (W Tons) Table 38. Global Viral Vaccines Revenue by Application (2021-2026) & (W Tons) Table 39. Global Viral Vaccines Revenue by Application (2027-2032) & (W Tons) Table 40. Global Viral Vaccines Revenue Market Share by Application (2021-2026) Table 41. Global Viral Vaccines Revenue Market Share by Application (2027-2032) Table 42. Global Viral Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Table 43. Global Viral Vaccines Sales by Region (2021-2026) & (W Tons) Table 44. Global Viral Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Viral Vaccines Sales Forecasted by Region (2027-2032) & (W Tons) Table 46. Global Viral Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 48. North America Viral Vaccines Sales by Country (2021-2026) & (W Tons) Table 49. North America Viral Vaccines Sales by Country (2027-2032) & (W Tons) Table 50. Europe Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 51. Europe Viral Vaccines Sales by Country (2021-2026) & (W Tons) Table 52. Europe Viral Vaccines Sales by Country (2027-2032) & (W Tons) Table 53. Asia Pacific Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 54. Asia Pacific Viral Vaccines Sales by Country (2021-2026) & (W Tons) Table 55. Asia Pacific Viral Vaccines Sales by Country (2027-2032) & (W Tons) Table 56. South America, Middle East and Africa Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 57. South America, Middle East and Africa Viral Vaccines Sales by Country (2021-2026) & (W Tons) Table 58. South America, Middle East and Africa Viral Vaccines Sales by Country (2027-2032) & (W Tons) Table 59. Global Viral Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Viral Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Viral Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Viral Vaccines Revenue Market Share by Region (2021-2026) Table 63. Global Viral Vaccines Revenue Market Share by Region (2027-2032) Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. GSK Viral Vaccines Product Portfolio Table 68. GSK Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Viral Vaccines Product Portfolio Table 73. Sanofi Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Viral Vaccines Product Portfolio Table 78. Novartis Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Merck Viral Vaccines Product Portfolio Table 83. Merck Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pfizer Viral Vaccines Product Portfolio Table 88. Pfizer Recent Development Table 89. Bayer Company Information Table 90. Bayer Business Overview Table 91. Bayer Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Bayer Viral Vaccines Product Portfolio Table 93. Bayer Recent Development Table 94. Zoetis Company Information Table 95. Zoetis Business Overview Table 96. Zoetis Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Zoetis Viral Vaccines Product Portfolio Table 98. Zoetis Recent Development Table 99. Johnson Company Information Table 100. Johnson Business Overview Table 101. Johnson Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Johnson Viral Vaccines Product Portfolio Table 103. Johnson Recent Development Table 104. CSL Company Information Table 105. CSL Business Overview Table 106. CSL Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. CSL Viral Vaccines Product Portfolio Table 108. CSL Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca Viral Vaccines Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. AstraZeneca Viral Vaccines Product Portfolio Table 113. AstraZeneca Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Viral Vaccines Distributors List Table 117. Viral Vaccines Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Viral Vaccines Product Image Figure 2. Global Viral Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Viral Vaccines Sales (2021-2032) & (W Tons) Figure 5. Global Viral Vaccines Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Viral Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Attenuated Vaccine Image Figure 9. Inactivated Vaccine Image Figure 10. Global Viral Vaccines Sales by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 11. Global Viral Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Viral Vaccines Sales Market Share by Type (2021-2032) Figure 13. Global Viral Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 14. Global Viral Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Viral Vaccines Revenue Market Share by Type (2021-2032) Figure 16. Research Institute Image Figure 17. Hospital Image Figure 18. Pharmaceutical Factory Image Figure 19. Others Image Figure 20. Global Viral Vaccines Sales by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 21. Global Viral Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Viral Vaccines Sales Market Share by Application (2021-2032) Figure 23. Global Viral Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 24. Global Viral Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Viral Vaccines Revenue Market Share by Application (2021-2032) Figure 26. North America Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 27. North America Viral Vaccines Sales Market Share by Country (2021-2032) Figure 28. U.S. Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 29. Canada Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 30. Mexico Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 31. Europe Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 32. Europe Viral Vaccines Sales Market Share by Country (2021-2032) Figure 33. Germany Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 34. France Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 35. U.K. Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 36. Italy Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 37. Netherlands Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 38. Asia Pacific Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 39. Asia Pacific Viral Vaccines Sales Market Share by Country (2021-2032) Figure 40. China Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 41. Japan Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 42. South Korea Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 43. Southeast Asia Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 44. India Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 45. Australia Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 46. South America, Middle East and Africa Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 47. South America, Middle East and Africa Viral Vaccines Sales Market Share by Country (2021-2032) Figure 48. Brazil Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 49. South Africa Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 50. Saudi Arabia Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 51. Turkey Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 52. Argentina Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 53. UAE Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 54. Egypt Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 55. Chile Viral Vaccines Sales and Growth Rate (2021-2032) & (W Tons) Figure 56. Global Viral Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Viral Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Viral Vaccines Revenue (2021-2032) & (US$ Million) Figure 59. North America Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Viral Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. Europe Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Viral Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Viral Vaccines Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Viral Vaccines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Viral Vaccines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated Vaccine
  • Inactivated Vaccine
Applications
  • Research Institute
  • Hospital
  • Pharmaceutical Factory
  • Others
Companies covered
  • GSK
  • Sanofi
  • Novartis
  • Merck
  • Pfizer
  • Bayer
  • Zoetis
  • Johnson
  • CSL
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Viral Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Viral Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Viral Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Viral Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Viral Vaccines Market Dynamics
  1. 2.1 Viral Vaccines Industry Trends
  2. 2.2 Viral Vaccines Industry Drivers
  3. 2.3 Viral Vaccines Industry Opportunities and Challenges
  4. 2.4 Viral Vaccines Industry Restraints
3 Viral Vaccines Market by Manufacturers
  1. 3.1 Global Viral Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Viral Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Viral Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Viral Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Viral Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Viral Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Viral Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Viral Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Viral Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Viral Vaccines Tier 1, Tier 2, and Tier 3
4 Viral Vaccines Market by Type
  1. 4.1 Viral Vaccines Type Introduction
  2. 4.1.1 Attenuated Vaccine
  3. 4.1.2 Inactivated Vaccine
  4. 4.2 Global Viral Vaccines Sales by Type
  5. 4.2.1 Global Viral Vaccines Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Viral Vaccines Sales by Type (2021-2032)
  7. 4.2.3 Global Viral Vaccines Sales Market Share by Type (2021-2032)
  8. 4.3 Global Viral Vaccines Revenue by Type
  9. 4.3.1 Global Viral Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Viral Vaccines Revenue by Type (2021-2032)
  11. 4.3.3 Global Viral Vaccines Revenue Market Share by Type (2021-2032)
5 Viral Vaccines Market by Application
  1. 5.1 Viral Vaccines Application Introduction
  2. 5.1.1 Research Institute
  3. 5.1.2 Hospital
  4. 5.1.3 Pharmaceutical Factory
  5. 5.1.4 Others
  6. 5.2 Global Viral Vaccines Sales by Application
  7. 5.2.1 Global Viral Vaccines Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Viral Vaccines Sales by Application (2021-2032)
  9. 5.2.3 Global Viral Vaccines Sales Market Share by Application (2021-2032)
  10. 5.3 Global Viral Vaccines Revenue by Application
  11. 5.3.1 Global Viral Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Viral Vaccines Revenue by Application (2021-2032)
  13. 5.3.3 Global Viral Vaccines Revenue Market Share by Application (2021-2032)
6 Global Viral Vaccines Sales by Region
  1. 6.1 Global Viral Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Viral Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Viral Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Viral Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Viral Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Viral Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Viral Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Viral Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Viral Vaccines Revenue by Region
  1. 7.1 Global Viral Vaccines Revenue by Region
  2. 7.1.1 Global Viral Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Viral Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Viral Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Viral Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Viral Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Viral Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Viral Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Viral Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Viral Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Viral Vaccines Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Viral Vaccines Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Viral Vaccines Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Viral Vaccines Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Viral Vaccines Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Viral Vaccines Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Zoetis
  38. 8.7.1 Zoetis Company Information
  39. 8.7.2 Zoetis Business Overview
  40. 8.7.3 Zoetis Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zoetis Viral Vaccines Product Portfolio
  42. 8.7.5 Zoetis Recent Developments
  43. 8.8 Johnson
  44. 8.8.1 Johnson Company Information
  45. 8.8.2 Johnson Business Overview
  46. 8.8.3 Johnson Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson Viral Vaccines Product Portfolio
  48. 8.8.5 Johnson Recent Developments
  49. 8.9 CSL
  50. 8.9.1 CSL Company Information
  51. 8.9.2 CSL Business Overview
  52. 8.9.3 CSL Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSL Viral Vaccines Product Portfolio
  54. 8.9.5 CSL Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Viral Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Viral Vaccines Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Viral Vaccines Value Chain Analysis
  2. 9.1.1 Viral Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Viral Vaccines Production Mode & Process
  6. 9.2 Viral Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Viral Vaccines Distributors
  9. 9.2.3 Viral Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst